Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Enliven Therapeutics Inc. (NASDAQ:ELVN), a $1.27 billion market cap biotech company, saw Chief Operating Officer Anish Patel sell 6,667 shares of common stock on October 7, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The stock has gained nearly 29% over the past six months, though InvestingPro analysis indicates the shares are currently trading above their Fair Value. The shares were sold at a weighted average price of $20.0979, for a total value of $133,992. The prices for the transactions ranged from $20.0001 to $20.22.
The sales were executed under a Rule 10b5-1 trading plan adopted on September 30, 2024, by Patel and The Patel / Dong Family Trust, for which Patel serves as trustee. Following the transaction, Patel directly holds 276,641 shares through The Patel / Dong Family Trust.
In other recent news, BTIG has reiterated its Buy rating on Enliven Therapeutics, maintaining a price target of $45. This decision is based on the potential of the company’s cancer treatment, ELVN-001, which is described as a well-designed, next-generation tyrosine kinase inhibitor. The research firm emphasized the drug’s differentiated efficacy and safety profile, which stands out in the chronic myeloid leukemia market, valued at approximately $9 billion. These developments suggest confidence from BTIG in Enliven Therapeutics’ strategic direction and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.